126 related articles for article (PubMed ID: 36476897)
1. [Effect of HDAC Inhibitor Chidamide on PD-L1 Expression in Peripheral T-Cell Lymphoma].
Yan MM; Li ZX; Chen C; Zhang W; Zhou DB
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Dec; 30(6):1741-1745. PubMed ID: 36476897
[TBL] [Abstract][Full Text] [Related]
2. Frequent amplification of HDAC genes and efficacy of HDAC inhibitor chidamide and PD-1 blockade combination in soft tissue sarcoma.
Que Y; Zhang XL; Liu ZX; Zhao JJ; Pan QZ; Wen XZ; Xiao W; Xu BS; Hong DC; Guo TH; Shen LJ; Fan WJ; Chen HY; Weng DS; Xu HR; Zhou PH; Zhang YZ; Niu XH; Zhang X
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33637599
[TBL] [Abstract][Full Text] [Related]
3. Aberrant JAK-STAT signaling-mediated chromatin remodeling impairs the sensitivity of NK/T-cell lymphoma to chidamide.
Chen J; Zuo Z; Gao Y; Yao X; Guan P; Wang Y; Li Z; Liu Z; Hong JH; Deng P; Chan JY; Cheah DMZ; Lim J; Chai KXY; Chia BKH; Pang JWL; Koh J; Huang D; He H; Sun Y; Liu L; Liu S; Huang Y; Wang X; You H; Saraf SA; Grigoropoulos NF; Li X; Bei J; Kang T; Lim ST; Teh BT; Huang H; Ong CK; Tan J
Clin Epigenetics; 2023 Feb; 15(1):19. PubMed ID: 36740715
[TBL] [Abstract][Full Text] [Related]
4. Effect of baricitinib in regulating programmed death 1 and ligand programmed cell death ligand 1 through JAK/STAT pathway in psoriasis.
Deepak HB; Prince SE; Deshpande P
Indian J Pharmacol; 2022; 54(3):183-193. PubMed ID: 35848689
[TBL] [Abstract][Full Text] [Related]
5. [Study on the Regulation of Chidamide on CD8
Yan MM; Li ZX; Chen C; Zhang W; Zhou DB
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Feb; 31(1):71-75. PubMed ID: 36765479
[TBL] [Abstract][Full Text] [Related]
6. Acute myeloid leukemias with JAK2/STAT mutations are associated with PD-L1 upregulation.
Chai J; Choudhuri J; Wang Q; Fang Y; Shi Y; Kamel J; Shah N; Sica RA; Kornblum N; Konopleva M; Mantzaris I; Shastri A; Gritsman K; Verma A; Goldfinger M; Goel S; Wang Y; Tian X
Leuk Lymphoma; 2023 Oct; 64(10):1662-1672. PubMed ID: 37424335
[TBL] [Abstract][Full Text] [Related]
7. Preclinical development and clinical studies of targeted JAK/STAT combined Anti-PD-1/PD-L1 therapy.
Chen M; Wang S
Int Immunopharmacol; 2024 Mar; 130():111717. PubMed ID: 38387193
[TBL] [Abstract][Full Text] [Related]
8. IL4I1 enhances PD-L1 expression through JAK/STAT signaling pathway in lung adenocarcinoma.
Zhu J; Li Y; Lv X
Immunogenetics; 2023 Feb; 75(1):17-25. PubMed ID: 36056935
[TBL] [Abstract][Full Text] [Related]
9. Orexin A Suppresses the Expression of Exosomal PD-L1 in Colon Cancer and Promotes T Cell Activity by Inhibiting JAK2/STAT3 Signaling Pathway.
Wen J; Chang X; Bai B; Gao Q; Zhao Y
Dig Dis Sci; 2022 Jun; 67(6):2173-2181. PubMed ID: 34097168
[TBL] [Abstract][Full Text] [Related]
10. Circulating PD-1 (+) cells may participate in immune evasion in peripheral T-cell lymphoma and chidamide enhance antitumor activity of PD-1 (+) cells.
Zhang W; Shen H; Zhang Y; Wang W; Hu S; Zou D; Zhou D
Cancer Med; 2019 May; 8(5):2104-2113. PubMed ID: 30969023
[TBL] [Abstract][Full Text] [Related]
11. In situ exploring Chidamide, a histone deacetylase inhibitor, induces molecular changes of leukemic T-lymphocyte apoptosis using Raman spectroscopy.
Xie Y; Tang P; Xing X; Zhao Y; Cao S; Liu S; Lu X; Zhong L
Spectrochim Acta A Mol Biomol Spectrosc; 2020 Nov; 241():118669. PubMed ID: 32653824
[TBL] [Abstract][Full Text] [Related]
12. Association of PD-L1 and IDO1 expression with JAK-STAT pathway activation in soft-tissue leiomyosarcoma.
Iwasaki T; Kohashi K; Toda Y; Ishihara S; Yamada Y; Oda Y
J Cancer Res Clin Oncol; 2021 May; 147(5):1451-1463. PubMed ID: 32951108
[TBL] [Abstract][Full Text] [Related]
13. SPIB Knockdown Inhibits the Immune Escape of Ovarian Cancer Cells by Reducing PD-L1 (CD274) Expression and Inactivating the JAK/STAT Pathway.
Gu W; Qi G; Chen L
Iran J Immunol; 2023 Sep; 20(3):335-347. PubMed ID: 37452634
[TBL] [Abstract][Full Text] [Related]
14. Chidamide plus Tyrosine Kinase Inhibitor Remodel the Tumor Immune Microenvironment and Reduce Tumor Progression When Combined with Immune Checkpoint Inhibitor in Naïve and Anti-PD-1 Resistant CT26-Bearing Mice.
Chen JS; Hsieh YC; Chou CH; Wu YH; Yang MH; Chu SH; Chao YS; Chen CN
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142591
[TBL] [Abstract][Full Text] [Related]
15. Essential thrombocythaemia progression to the fibrotic phase is associated with a decrease in JAK2 and PDL1 levels.
Lewandowski K; Kanduła Z; Gniot M; Paczkowska E; Nawrocka PM; Wojtaszewska M; Janowski M; Mariak M; Handschuh L; Kozlowski P
Ann Hematol; 2022 Dec; 101(12):2665-2677. PubMed ID: 36266510
[TBL] [Abstract][Full Text] [Related]
16. JAK2 and PD-L1 Amplification Enhance the Dynamic Expression of PD-L1 in Triple-negative Breast Cancer.
Chen M; Pockaj B; Andreozzi M; Barrett MT; Krishna S; Eaton S; Niu R; Anderson KS
Clin Breast Cancer; 2018 Oct; 18(5):e1205-e1215. PubMed ID: 29933930
[TBL] [Abstract][Full Text] [Related]
17. JAK-STAT1 Signaling Pathway Is an Early Response to
Li X; Pan K; Vieth M; Gerhard M; Li W; Mejías-Luque R
Int J Mol Sci; 2022 Apr; 23(8):. PubMed ID: 35456965
[No Abstract] [Full Text] [Related]
18. Oncogenic activation of the STAT3 pathway drives PD-L1 expression in natural killer/T-cell lymphoma.
Song TL; Nairismägi ML; Laurensia Y; Lim JQ; Tan J; Li ZM; Pang WL; Kizhakeyil A; Wijaya GC; Huang DC; Nagarajan S; Chia BK; Cheah D; Liu YH; Zhang F; Rao HL; Tang T; Wong EK; Bei JX; Iqbal J; Grigoropoulos NF; Ng SB; Chng WJ; Teh BT; Tan SY; Verma NK; Fan H; Lim ST; Ong CK
Blood; 2018 Sep; 132(11):1146-1158. PubMed ID: 30054295
[TBL] [Abstract][Full Text] [Related]
19. SOX2 promotes resistance of melanoma with PD-L1 high expression to T-cell-mediated cytotoxicity that can be reversed by SAHA.
Wu R; Wang C; Li Z; Xiao J; Li C; Wang X; Kong P; Cao J; Huang F; Li Z; Huang Y; Chen Y; Li X; Yang D; Zhang H; Mai J; Feng G; Deng R; Zhu X
J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33158915
[TBL] [Abstract][Full Text] [Related]
20. Histone deacetylases inhibitor chidamide synergizes with humanized PD1 antibody to enhance T-cell chemokine expression and augment Ifn-γ response in NK-T cell lymphoma.
Wen T; Sun G; Jiang W; He X; Shi Y; Ma F; Liu P
EBioMedicine; 2023 Jan; 87():104420. PubMed ID: 36592514
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
